BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  US Device


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Moderna Therapeutics, Inc. 

200 Tech Square

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-714-6500 Fax: 617-583-1998


Moderna is pioneering messenger RNA therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellular or secreted. This breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions.

Our novel chemistry enables messenger RNA to elude the body’s innate immune response. Once delivered, stable messenger RNA is translated into active, native protein by cells’ natural, well-tuned machinery for protein production. To date, we have made great strides in advancing messenger RNA as a drug platform, and have screened more than 100 new chemistries. Our current formulation represents a 50-fold increase in in vivo protein expression over our first generation chemistry, even as we have exponentially reduced the cost associated with manufacturing our messenger RNA Therapeutics™. We have also developed a broad intellectual property estate including 200 patent applications with 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions.

Moderna plans to develop and commercialize its innovative mRNA drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients.

Based in Cambridge, Massachusetts, Moderna is privately held and was founded in 2010 by Flagship VentureLabs in association with leading scientists from Boston Children’s Hospital and Massachusetts Institute of Technology.

 Key Statistics

Ownership: Private

Web Site: Moderna Therapeutics, Inc.


 Company News
Moderna Therapeutics, Inc. Appoints Biotechnology Investment Banking Veteran Lorence Kim As Chief Financial Officer 3/6/2014 6:51:02 AM    More...
Rich With $20 Million And 15 Preclinical Candidates, Moderna Therapeutics, Inc. Spins Out MRNA Cancer Drugs Into New Company 1/15/2014 6:46:19 AM    More...
Alexion Pharmaceuticals Inc. (ALXN), Moderna Therapeutics, Inc. Ink $100 Million Rare-Disease Pact 1/13/2014 7:22:49 AM    More...
Moderna Therapeutics, Inc. To Present At 32nd Annual J.P. Morgan Healthcare Conference 1/6/2014 6:29:40 AM    More...
Moderna Therapeutics, Inc. Appoints Theo Melas-Kyriazi To Board of Directors 12/17/2013 6:59:58 AM    More...
Moderna Therapeutics Sucks Up Another $110 Million To Make Messenger RNA Drugs 11/20/2013 7:32:56 AM    More...
Moderna Therapeutics Named to the World Economic Forum's Community of "Global Growth Companies" 10/24/2013 11:12:02 AM    More...
Moderna Therapeutics Expands New Headquarters, Laboratories in Cambridge; Plans to Up Headcount to 100 Full-Time Staffers by End of Year 10/17/2013 10:12:01 AM    More...
Moderna Therapeutics Grabs $25 Million Defense Advanced Research Projects Agency Grant to Develop Messenger RNA Therapeutics™ 10/2/2013 7:16:09 AM    More...
Study Published in Nature Biotechnology Demonstrates Ability of Moderna Therapeutics's Novel Therapeutic Paradigm to Repair and Regenerate Damaged Heart Tissue 9/9/2013 8:32:56 AM    More...